Madopar

Levodopa/Benserazide Hydrochloride, the active ingredients in Madopar, are antiparkinson agents presented as oral tablets for oral use. They are prescribed to manage the motor symptoms of Parkinson's disease and related Parkinsonian syndromes by increasing dopamine availability in the brain.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar is used in the management of Parkinsonian disorders, targeting dopaminergic pathways to improve motor function. - Parkinson's disease: reduces rigidity, bradykinesia and tremor, enhancing daily activity performance. - Parkinsonian syndrome: alleviates motor deficits caused by idiopathic or secondary Parkinsonism. - Drug‑induced Parkinsonism: mitigates symptoms when antipsychotic‑induced dopamine blockade is present.

Madopar may cause a range of adverse reactions, most of which are dose‑related and reversible upon adjustment.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Dyskinesia: involuntary movements, especially at higher doses. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation. - Mood changes: anxiety or depression.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening hyperthermia and rigidity. - Severe cardiac arrhythmias: rare but potentially fatal. - Hallucinations: visual or auditory disturbances. - Severe orthostatic hypotension leading to falls.

When prescribing Madopar, clinicians should consider patient‑specific factors and monitor for adverse events. - Renal impairment: adjust dose as clearance may be reduced. - Hepatic dysfunction: use caution due to altered metabolism. - Concomitant MAO‑B inhibitors: avoid combined use to reduce risk of hypertensive crisis. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Elderly patients: start with low dose and titrate slowly to minimize dyskinesia. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Madopar interacts with several drug classes that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics with strong D2 antagonism (e.g., haloperidol): may negate therapeutic effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance orthostatic hypotension. - Iron or calcium supplements: can reduce levodopa absorption; separate dosing by at least 2 hours. - SSRIs and SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.